Bank of New York Mellon Corp Has $57.10 Million Stock Holdings in DaVita Inc. (NYSE:DVA)

Bank of New York Mellon Corp trimmed its position in DaVita Inc. (NYSE:DVA - Free Report) by 8.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 381,794 shares of the company's stock after selling 35,664 shares during the period. Bank of New York Mellon Corp owned approximately 0.47% of DaVita worth $57,097,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of DVA. Transcendent Capital Group LLC bought a new stake in DaVita during the 3rd quarter worth approximately $25,000. Quarry LP bought a new stake in DaVita during the 3rd quarter worth approximately $60,000. Venturi Wealth Management LLC increased its stake in DaVita by 59.8% during the 4th quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock worth $61,000 after purchasing an additional 152 shares in the last quarter. Versant Capital Management Inc increased its stake in DaVita by 58.7% during the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company's stock worth $68,000 after purchasing an additional 169 shares in the last quarter. Finally, Blue Trust Inc. increased its stake in DaVita by 39.7% during the 4th quarter. Blue Trust Inc. now owns 461 shares of the company's stock worth $76,000 after purchasing an additional 131 shares in the last quarter. 90.12% of the stock is owned by institutional investors.

Analysts Set New Price Targets

DVA has been the subject of a number of research reports. Barclays increased their target price on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a research note on Friday, February 21st. Finally, Cowen reaffirmed a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $166.33.

Remove Ads

DaVita Stock Up 4.5 %

Shares of NYSE DVA traded up $6.37 during trading hours on Friday, hitting $146.73. The company had a trading volume of 1,099,255 shares, compared to its average volume of 788,373. The stock has a market capitalization of $11.74 billion, a P/E ratio of 13.66, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 1-year low of $125.64 and a 1-year high of $179.60. The firm's 50 day moving average is $159.58 and its 200-day moving average is $157.87.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $2.24 EPS for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.